CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A comprehensive planning guide for zero based budgeting can enhance your financial strategy. Learn to optimize spending and achieve goals.
20,214 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Markets react to renewed US pressure on Iran as Trump signals possible seizure actions, raising questions about suppl...
Investors are torn between rate hikes and rate cuts as inflation stays stubborn. Wall Street can't decide the Fed's p...
A bold move by Oracle in the AI data-center space could reshape demand for NVIDIA GPUs. This article explains what th...
Investors rally around earnings season, but the big question remains: should abbott labs stock be part of your plan b...
Ray Dalio wraps a 10-day China-focused Asia tour, warning that a realignment of global power could reshape markets an...
As housing costs stretch budgets, industry observers turn to the ROAD to Housing Act for relief. BOK Financial’s Mich...
As the Fed considers stricter rules for stablecoins, Circle’s USDC stands to gain in trust and adoption. This deep-di...
Finance Of America has closed an all-cash acquisition of Onity’s reverse mortgage servicing rights, adding roughly 20...
intel stock bounced back today after a rough stretch for the sector. This article breaks down the what, why, and how ...
In a rapid turn of events, Bayer rode a Supreme Court win on Roundup lawsuits, then pressed for glyphosate tariffs. F...
In a volatile market, the dividend growth approach that emphasizes rising payouts over big yields is drawing attentio...